Annals of oncology : official journal of the European Society for Medical Oncology
-
Randomized Controlled Trial
Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.
In the coBRIM phase III trial, the addition of cobimetinib, an MEK inhibitor, to vemurafenib, a BRAF inhibitor, significantly improved progression-free survival [hazard ratio (HR), 0.58; P < 0.0001] and overall survival (HR, 0.70; P = 0.005) in advanced BRAF-mutated melanoma. Here, we report on the incidence, course, and management of key adverse events (AEs) in the coBRIM study. ⋯ NCT01689519.